Fertipig. Power with Control. i t s. ec o. ys a. 2 o

Transcription

1 Fertipig Power with Control da 8 2 o t Stable for up rr e t f ys a n o i ut t i t s n ec o

2

3 Fertipig Power with Control Meet breeding targets The main goal of breeding herds is to consistently meet breeding targets. Weaned sows failing to return to oestrus within 7 days after weaning contribute to missed breeding targets and increased non-productive days (NPD). Longer lapse between weaning and oestrus together with real anoestrus contribute to the inability to completely fill vacant farrowing places and increased NPD costs. FOLLICLE DEVELOPMENT FOLLICLE ATRESIA LH WEANING FSH LH OESTRADIOL OVULATION << Both gonadotrophins FSH and LH are important in the early phase afer weaning for the correct selection and growth of the preovulatory follicles, which will finally ovulate afer the LH surge << The combination of 400IU ecg and 200IU of hcg mimics the action of FSH and LH when administered early after weaning and is able to induce a fertile oestrus with strong behavioural presence of heat in sows treated at weaning or in sows with anoestrus. Adapted from Foxcroft The proper use of hcg+ecg allows you to meet your breeding targets and reduce NPD on farm Induce High Quality Oestrus Fertile oestrus Clearly visible High ovulation rate Reduce WOI Parity (especially first parity), season, duration of lactation and energy balance can influence the duration of the weaning oestrus interval (WOI). The breeding target should be mimimum 95% of sows in heat within 5 days and inseminated within 7 days afer weaning. When those breeding targets are not being met, administration of ecg/hcg shortly after weaning can make the average WOI shorter. Prevent Anoestrus Anoestrus after weaning may be observed particularly in the summer season, in primiparous sows or in cases of low energy balance. An effective strategy during the periods when anoestrus is likely to occur is to treat all sows at weaning with ecg/hcg combination. 3 Individual treatment of sows not in heat within 7 days post weaning may result in fertile oestrus. 4

4 Ceva Repro Range The Correct use of Fertipig Building on the knowledge of the oestrus cycle and breeding targets, treatment with Fertipig may be implemented either in a preventive way to all weaned sows in the batch at the day of weaning, or selectively to sows which are not in heat within 7 days after weaning. Fertipig USES When do we treat? Induction and synchronisation of oestrus Prevention of anoestrus Throughout the year Breeding targets are not achieved Seasonal anoestrus In summer Breeding targets are not achieved Prevention of silent heat Sow not in heat >7 days post weaning Treatment of seasonal anoestrus Reduction of WOI in sows with late oestrus Lower WOI, better synchronisation of oestrus <7 Average WOI < 7 days

5 Fertipig Power with Control Fertipig Power with Control The Ceva product combining 400IU of ecg and 200IU of hcg in the lyophilized form as lyophilisate. Which animals? Goals All sows at weaning All sows at weaning in summer season Higher insemination rate All sows at weaning Sow not in heat >7 days post weaning Higher piglet index All sows at weaning Less nonproductive days (NPD) Improved concentration at work

6 Ceva Repro Range Fertipig improves on farm performance Better performance with Fertipig by induction and synchronisation of oestrus. 5 WOI INSEMINATION RATE PIGLET INDEX WEAN - Oestrus (in h) 2 Percent of pregnancy or farrowing Superior reproductive performance when Fertipig is used to induce and synchronise groups of sows vs competitor on a farm with low reproductive performances due to seasonal impact. 6 Fertipig treated sows had the tendency (p<0.)to higher pregnancy and the farrowing rate as well as to bigger litter size. 80% 75% 70% 65% 60% 79.50% CONTROL Data from Farm A in the study 76.80% 72.40% Insemination Rate (in %) 00 Pregnancy % Farrowing % 68.60% PRODUCT P Comparison of pregnancy and farrowing rate << 96% of sows treated with Fertipig were in heat within 6 days afer weaning with the average weaning-to-insemination interval 4.08 days Number of piglets CONTROL Data from Farm A in the study 4 3,5 3 2,5 2, PL (Piglets/00 sows) CONTROL Data from Farm A in the study PRODUCT P Mean number of total born and live born piglets per group Piglets total born Piglets live born << 3 Higher treatment rate of anoestrus in sows vs competitor Sows in heat within 7 days post treatment Sows that did not exhibit signs of oestrus within 7 days after weaning were treated with Fertipig (23 sows) within the period of 7-2 days after weaning or with product G (which contains PMSG and HCG) routinely used in the farms previously (3 sows). 7 << Fertipig treated sows had higher fertility * >> * However the difference were not statistically significant (p>0.05) Percentage from the initial number of sows PRODUCT G OESTRUS RATE PREGNANCY RATE FARROWING RATE Comparison of pregnancy and farrowing rates

7 Fertipig Power with Control Better stability-easy use UNIQUE PRODUCT STABLE FOR UP TO 28 DAYS Stable for up to 28 days afer reconstitution While all competitors products must be used after the reconstitution immediately or within 2 hours, Fertipig has proven stability of ecg and hcg activities and sterility for up to 4 weeks after reconstitution. 8 Stability of ecg and hcg in Fertipig <<Fertipig uniquely has officially approved stability for up to 28 days afer reconstitution, store in a refrigerator (2 C - 8 C)>> T0 T+3 W IU/dose T+5 W 0 ecg hcg Benefits of long stability-in-use Better drugs inventory management How to plan the stock? Nº of sows to be treated Competitor Fertipig Week 7 5 ds Week 2 5 ds 5 ds Week ds Only presentation Week ds 5 ds required to fit your needs! POWER WITHOUT CONTROL LEADS TO WASTAGE

8 Fertipig Power with Control Induction and synchronisation of oestrus. Reduction of WOI. Unique stability with 28 days of use afer reconstitution. Easy planning of purchase and use. Better drugs inventory management. SPECIES ADMINISTRATION ROUTE DOSAGE Pigs (Sows) IM 5ml once after weaning CONTRAINDICATIONS: Do not administer to pregnant animals. Do not administer to animals with known hypersensitivity to the active substances or to any of the excipients. Do not administer to sows with follicular cysts. SPECIAL WARNINGS: Treatment during the primary luteinised phase or in the middle of the cycle may increase the risk of ovarian cysts development. Do not adjust the dose. Increased doses do not increase the efficacy of the product. SPECIAL PRECAUTIONS FOR USE IN ANIMALS: Do not inject into the subcutaneous fat. SPECIAL PRECAUTIONS TO BE TAKEN BY THE USER: Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after handling the product. The product can cause a slight skin irritation. When the product comes into contact with the skin, rinse immediately with plenty of water. Pregnant women, women intending to become pregnant or whose pregnancy status is unknown, should not use the product due to the risk of unintended self-injection. Studies in laboratory animals exhibited dose-dependent teratogenic effects after the administration of the combination HCG / PMSG. People with known hypersentivity to gonadotrophins should avoid contact with the product. ADVERSE REACTIONS: In rare cases anaphylactic shock is seen by repeated administration of PMSG and HCG, since PMSG and HCG are exogenous proteins for other species than equine and human and therefore can provoke an antigen-antibody reaction. In case of anaphylactic shock, appropriate treatment should be administered. The frequency of possible adverse reactions is defined using the following convention: very common (affects more than animal in 0) common (affects to 0 animals in 00) uncommon (affects to 0 animals in,000) rare (affects to 0 animals in 0,000) very rare (affects less than animals in 0,000) not known (frequency cannot be estimated from the available data). USE DURING PREGANCY, LACTATION & LAY: Do not administer to pregnant animals. Laboratory studies in laboratory animals have shown evidence of teratogenic effects after combined use of PMSG and HCG. INTERACTION WITH OTHER MEDICAL PRODUCTS: None known. AMOUNT(S) TO BE ADMINISTERED AND ADMINISTRATION ROUTE: Intramuscular use. Dissolve the lyophilisate with a small quantity of solvent. Mix to obtain a homogenous solution. Transfer this solution into the vial that contains the rest of the solvent. Shake the vial well to obtain homogenous solution. 400 IU of equine serum gonadotrophin and 200 IU of chorionic gonadotrophin per animal, i.e. 5 ml of the reconstituted solution in one administration within 24 hours after the weaning. OVERDOSE (SYMPTOMS, EMERGENCY PROCEDURES, AND ANTIDOTES) IF NECESSARY: A transient increase in progesterone level was observed following administration of 3 times the recommended dose, following the first oestrus. An induration and a transient erythema have been observed at the injection site during the product administration with three times the therapeutic dose. The daily administration of the therapeutic dose during 2 consecutive days can lead to the occurrence of ovarian cysts. WITHDRAWAL PERIOD: Meat and offal: zero days. LEGAL CATEGORY: UK POM-V IE POM MARKETING AUTHORISATION: Vm 5052/4050 Further information is available on the data sheet Reference List Patterson JL, et al. J Swine Health Prod. 200;8(4): Foxcroft, R.G. 2002, Seminar on Optimizing Reproductive Efficiency at the 35th AASV Annual Meeting, Iowa 3 Almond G.W. et al B.E. Diseases of swine, 9th edition, S.P. Franek,et al. Weaning on Selected Reproductive Indicators of the Sow, Acta Vet. Brno 2008, 77: Pabst T., Proceedings Trends in sow reproduction, 20 6 Krejci R. et al. Proceedings IPVS 202, 92 7 Krejci R. et al. Proceedings IPVS 202, 93 8 Ceva- Internal data L Use medicines responsibly ( Further information is available from Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB Tel: cevauk@ceva.com